logo-loader
Helius Medical Technologies

Helius Medical gets Canadian boost with three new clinics authorized to use brain device

The Portable Neuromodulation Stimulator is a noninvasive medical device to treat chronic balance issues stemming from traumatic brain injury

Finger pointing to brain
The Portable Neuromodulation Stimulator is a noninvasive medical device to treat chronic balance issues from brain injury

Helius Medial Technologies Inc (TSE:HSM) (NASDAQ:HSDT) got a major boost on Wednesday after the neurotech company announced that its Portable Neuromodulation Stimulator device is now available in three Canadian clinics.

The Portable Neuromodulation Stimulator (PoNS) is a noninvasive medical device to treat chronic balance issues stemming from traumatic brain injury. The prescription-only product is used in conjunction with a physical therapy regimen.

Shares of Helius soared in both the US and Canada, up 13.5% in New York to US$3.20 and 15.3% in Toronto at C$4.37.

READ: LexaGene hits major milestone, places its pathogen-detecting technology in major Massachusetts veterinary hospital

Pennsylvania-based Helius opened its first authorized clinic in the province of Quebec in December 2018 and the second in February of this year in British Columbia. In addition to the two existing clinics, Helius now adds two Ontario and one Alberta-based location.

“We are pleased that the strategy to accelerate expansion plans in Canada has driven the further development of the clinic system authorized to provide PoNS Treatment,” said Philippe Deschamps, CEO of Helius in a statement. 

“Patients who have had mild-to-moderate traumatic brain injuries are often not able to travel long distances and now, with a presence in Montreal, Vancouver, Toronto, Calgary and Ottawa, over 50% of Canadians will have direct local access to PoNS Treatment.”

The PoNS is an investigational medical device in the United States, the European Union, and Australia and is not currently commercially available outside of Canada.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Helius Medical Technologies

Price: £0.00

Market: CSE
Market Cap: £0.00
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Arcadia Biosciences makes major progress on its hemp venture...

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Raj Ketkar tells Proactive the California-based company expects to “significantly scale revenues in 2020” as it reported financial and business results for the second quarter and first half of 2019. Ketkar says the agricultural innovation company made...

2 days, 8 hours ago

RNS

Result of AGM

1 week, 3 days ago

Holding(s) in Company

on 07/15/2019

Final Results

on 07/11/2019

PDMR/PCA Dealing

on 04/01/2019

Half-year Report

on 11/08/2018

Result of AGM

on 08/10/2018

Final Results

on 07/12/2018

Dividend Record Date

on 01/15/2018

2 min read